期刊文献+

碳酸镧治疗终末期肾脏病患者高磷血症的临床分析 被引量:5

下载PDF
导出
摘要 目的:对应用碳酸镧出现高磷血症的终末期肾脏病患者实施药物治疗的临床效果进行研究。方法:选择收治的出现高磷血症的终末期肾脏病患者92例,采用随机数字表法分为两组,每组46例,分别命名为对照组和治疗组。采用碳酸钙对对照组患者的病情实施药物干预;采用碳酸镧对治疗组患者的病情实施药物干预。对比两组患者在药物干预前后相关指标水平的改善幅度、终末期肾脏病高磷血症的药物控制总有效率、用药期间出现的不良反应例数、血磷水平用药后恢复正常时间和用药治疗总时间。结果:在药物干预前后治疗组相关指标水平的改善幅度较对照组大;终末期肾脏病高磷血症的药物控制总有效率明显高于对照组;用药期间出现的不良反应例数明显少于对照组;血磷水平用药后恢复正常时间、治疗总时间较对照组明显缩短,差异有统计学意义(P<0.05)。结论:应用碳酸镧对出现高磷血症的终末期肾脏病患者实施药物治疗的临床效果非常明显。
作者 潘健忠
出处 《吉林医学》 CAS 2018年第1期129-130,共2页 Jilin Medical Journal
  • 相关文献

参考文献5

二级参考文献83

  • 1王英,王梅.终末期肾病患者钙磷代谢异常与血管钙化[J].中国血液净化,2006,5(3):152-155. 被引量:13
  • 2Kates DM, Andress DL: Control of hyperphosphatemia in renal failure: role of aluminum. Semin Dial, 9:301-315, 1996.
  • 3Sperschneider H, Gunther K, Marzoll I, et al. Calcium carbonate(CaCO3): an efficient and safe phosphate binder in haemodialysis patients? A 3-year study, Nephrol Dial Transplant, 1993; 8:530-534.
  • 4Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. NEnglJMed, 2000; 342(485): 1478-1483.
  • 5Schaefer K. Alternative phosphate binders: an update. Nephrol Dial Transplant, 1993; 1(2): 35-39.
  • 6Locatelli F, D'Amico M. Lanthanum carbonate AnorMED. Curr Opin Cardiovasc Pulmon Renal Invest Drugs, 2000; 2 (4): 372-377.
  • 7D'Haese PC. Spasovski GB. Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International-Supplement, 2003; 1(85): S73-78.
  • 8Joy MS, Finn WF. LAM-302 Study Group; Randomized, doubleblind, placebo-controlled, dose-titration, phase Ⅲ study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. American Journal of Kidney Diseases, 2003; 42(1): 96-107.
  • 9Finn WE Joy MS, Hladik G. Lanthanum Study Group; Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clinical Nephrology, 2004; 62(3): 193-201.
  • 10Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol)efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clinical Nephrology, 2005;63(6): 461-470.

共引文献55

同被引文献35

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部